In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Xoma Corp (NASDAQ: XOMA), with a price target of $33. The company’s shares closed on Friday at $24.73.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.3% and a 45.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Xoma Corp is Moderate Buy and the average price target is $41, representing a 65.8% upside.
In a report issued on May 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $49 price target.
See today’s analyst top recommended stocks >>
Xoma Corp’s market cap is currently $206.1M and has a P/E ratio of 17.92. The company has a Price to Book ratio of 36.55.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.
